1 Result(s)

Article

Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM

In Hong Kong, newly diagnosed multiple myeloma (NDMM) receives bortezomib-based triplet induction. Upfront autologous stem cell transplant (ASCT) is offered to transplant eligible (TE) patients (NDMM ≤ 65 year...

Hoi Ki Karen Tang, Chi Yeung Fung, Yu Yan Hwang, Harold Lee… in Bone Marrow Transplantation (2024)